Association of severity of menstrual dysfunction with cardiometabolic risk markers among women with polycystic ovary syndrome.

Autor: Li X; Reproductive Medicine Center, Shunde Hospital of Southern Medical University (The First People's Hospital of Shunde), Foshan, Guangdong, China., Yang J; Reproductive Medicine Center, Shunde Hospital of Southern Medical University (The First People's Hospital of Shunde), Foshan, Guangdong, China., Blockeel C; Brussels, IVF, center for Reproductive Medicine, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium., Lin M; Reproductive Medicine Center, Shunde Hospital of Southern Medical University (The First People's Hospital of Shunde), Foshan, Guangdong, China., Tian X; Reproductive Medicine Center, Shunde Hospital of Southern Medical University (The First People's Hospital of Shunde), Foshan, Guangdong, China., Wu H; Department of Clinical Laboratory, Shunde Hospital of Southern Medical University (The First People's Hospital of Shunde), Foshan, Guangdong, China., Cao Y; College of Science, Minzu University of China, Beijing, China., Deng L; Reproductive Medicine Center, Shunde Hospital of Southern Medical University (The First People's Hospital of Shunde), Foshan, Guangdong, China., Zhou X; Reproductive Medicine Center, Shunde Hospital of Southern Medical University (The First People's Hospital of Shunde), Foshan, Guangdong, China., Xie J; College of Science, Minzu University of China, Beijing, China., Hu Y; Department of Cardiology, Shunde Hospital of Southern Medical University (The First People's Hospital of Shunde), Foshan, Guangdong, China., Chen X; Reproductive Medicine Center, Shunde Hospital of Southern Medical University (The First People's Hospital of Shunde), Foshan, Guangdong, China.
Jazyk: angličtina
Zdroj: Acta obstetricia et gynecologica Scandinavica [Acta Obstet Gynecol Scand] 2024 Aug; Vol. 103 (8), pp. 1606-1614. Date of Electronic Publication: 2024 May 07.
DOI: 10.1111/aogs.14863
Abstrakt: Introduction: Polycystic ovary syndrome (PCOS) is associated with a wide range of unfavorable cardiometabolic risk factors, including obesity, hypertension, insulin resistance, impaired glucose metabolism, dyslipidemia, and metabolic syndrome. Compared with women with regular menstrual cycles, women with a history of irregular menstrual periods have an increased unfavorable cardiometabolic risk. Recently, the association between the severity of oligomenorrhea and hyperinsulinemia and insulin resistance has been demonstrated. However, evidence linking the severity of menstrual cyclicity with cardiometabolic risk in PCOS women is scarce.
Material and Methods: This work was a prospective cross-sectional study. A total of 154 women diagnosed with PCOS by the Rotterdam criteria were recruited from July 2021 to September 2022. PCOS women with eumenorrheic (eumeno group), oligomenorrhea (oligo group), and amenorrhea (ameno group) underwent history and physical examination, gonadal steroid hormone measurement, lipid profile, oral glucose tolerance test, and homeostasis model assessment of insulin resistance.
Results: A trend toward an increase in unfavorable cardiometabolic risk markers including obesity, hypertension, prevalence of insulin resistance, prediabetes, dyslipidemia, and metabolic syndrome was observed in the ameno group (n = 57) as compared with the eumeno (n = 24) or oligo group (n = 73). A higher prevalence of insulin resistance (odds ratio [OR]: 3.02; 95% confidence interval [CI]: 1.03-8.81) and prediabetes (OR: 3.94; 95% CI: 1.01-15.40) was observed in the ameno group than in the eumeno group, and a higher proportion of dyslipidemia (OR: 2.44; 95% CI: 1.16-5.15) was observed in the ameno group than in the oligo group in the binary logistic regression analysis after adjusting for confounding factors.
Conclusions: PCOS women with amenorrhea show a higher prevalence of insulin resistance, prediabetes, and dyslipidemia compared with those with oligomenorrhea or eumenorrhea. The severity of menstrual dysfunction could be used as a readily obtainable marker for the identification of PCOS women at greatest risk of cardiometabolic diseases.
(© 2024 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG).)
Databáze: MEDLINE
Externí odkaz: